Indegene Limited has completed an internal restructuring transaction involving the acquisition of 100% equity shares in Trilogy Writing & Consulting Inc., a Canada-based medical writing company. The acquisition was finalized on December 31, 2025, through a Share Purchase Agreement signed by the company's wholly owned subsidiaries.

Transaction Structure

The acquisition was executed by Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH, both wholly owned subsidiaries of Indegene Limited. The transaction involved acquiring 100% equity shares in Trilogy Writing & Consulting Inc., formerly known as Trilogy Writing and Consulting ULC (Canada).

Target Company Profile

Trilogy Writing & Consulting Inc. is a Canada-based company specializing in medical writing services. The company operates within the healthcare industry and has demonstrated consistent growth in recent years.

The target company's turnover has shown significant growth, increasing from CAD 369,636 in 2022 to CAD 892,361 in 2024, representing substantial year-over-year expansion in its medical writing business.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that:

• The transaction falls within related party transactions
• No promoter, promoter group, or group companies have any interest in the entity being acquired
• The transaction was conducted on an arm's length basis
• No governmental or regulatory approvals were required for the acquisition

Post-Acquisition Structure

Following the completion of this internal restructuring, Trilogy Writing & Consulting Inc. will cease to be a subsidiary of Trilogy Writing and Consulting GmbH and will become a wholly owned subsidiary of Indegene, Inc. This restructuring aligns with the company's strategic organizational objectives while maintaining full control over the medical writing capabilities of the acquired entity.

The acquisition strengthens Indegene's presence in the medical writing sector and enhances its service offerings within the healthcare industry. The transaction represents a strategic internal reorganization designed to optimize the company's subsidiary structure and operational efficiency.

Indegene Limited , a prominent player in the Indian healthcare technology sector, has announced a significant board development. The company's Board of Directors approved the reappointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director for a five-year term on December 19, 2025, marking his return to the board in a new capacity.

Board Appointment Details

The board approval came based on the recommendation of the Nomination and Remuneration Committee. The appointment details are outlined below:

Director Profile and Qualifications

Mr. Bharadwaj brings substantial academic credentials and professional experience to the board. He holds a Bachelor of Science in Economics with a specialization in Finance from the University of Pennsylvania, Philadelphia, and an MBA in Management from Harvard University, Cambridge, Massachusetts.

His professional expertise spans multiple areas:

Regulatory Compliance and Governance

Indegene Limited has ensured full compliance with regulatory requirements for this appointment. The company confirmed that Mr. Bharadwaj is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority, as required under NSE and BSE circulars.

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also confirmed that Mr. Bharadwaj is not related to any existing Director of the company.

Additional Board Matters

During the same board meeting, the directors also approved allotments under the company's ESOP Plan 2020 and RSU Plan 2020, demonstrating continued focus on employee incentive programs.

Srishti Ramesh Kaushik, Company Secretary and Compliance Officer of Indegene Limited, confirmed that all relevant information has been made available on the company's official website at https://www.indegene.com/ .

This reappointment reflects the company's confidence in Mr. Bharadwaj's expertise and his potential contribution to Indegene's strategic direction in the evolving healthcare technology sector.